Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

11%

1 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

4(66.7%)

Phase 2

1(16.7%)

Phase 4

1(16.7%)

6Total

N/A(4)

Phase 2(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT03688165Completed

The Effects of Gait Rehabilitation After Stroke by Treadmill-based Robotics Versus Traditional Gait Training

Role: collaborator

NCT04694742Unknown

Ventilatory Efficiency in Critically Ill COVID-19 Patients

Role: collaborator

NCT03917368Not ApplicableUnknown

Ultrasound Evaluation of the Jugular Venous Pulse (US-JVP)

Role: lead

NCT02306109Not ApplicableCompleted

Effect of Motor Rehabilitation Treatment on Amyotrophic Lateral Sclerosis (ALS)

Role: collaborator

NCT02801968Not ApplicableUnknown

Tap Block and Cesarean Delivery: Efficacy and Consumption of Postoperative Drugs

Role: lead

NCT01371760Not ApplicableCompleted

BRAVE-DREAMS (BRAin VEnous DRainage Exploited Against Multiple Sclerosis)

Role: lead

NCT02319083Unknown

Outcome After Coronary Artery Bypass Grafting

Role: collaborator

NCT00566891Phase 4Completed

Safety of High-dose Tirofiban During Coronary Angioplasty

Role: lead

NCT00998361Phase 2Unknown

Hematopoietic Stem Cell Transplantation From Human Leukocyte Antigen (HLA) Compatible Donor in Ewing Sarcomas and Soft Tissues Sarcomas

Role: collaborator

All 9 trials loaded